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SUMMARY
Central to cellular proliferative, survival, and metabolic responses is the serine/threonine kinase mTOR, which is activated in many
human cancers. mTOR is present in distinct complexes that are either modulated by AKT (mTORC1) or are upstream and regulatory
of it (mTORC2). Governance of mTORC2 activity is poorly understood. Here, we report a transmembrane molecule in hematopoietic
progenitor cells that physically interacts with and inhibits RICTOR, an essential component of mTORC2. Upstream of mTORC2
(UT2) negatively regulates mTORC2 enzymatic activity, reducing AKT
S473, PKCa, and NDRG1 phosphorylation and increasing FOXO
transcriptional activity in an mTORC2-dependent manner. Modulating UT2 levels altered animal survival in a Tcell acute lymphoid leu-
kemia (T-ALL) model that is known to be mTORC2 sensitive. These studies identify an inhibitory component upstream of mTORC2 in
hematopoietic cells that can reduce mortality from NOTCH-induced T-ALL. A transmembrane inhibitor of mTORC2 may provide an
attractive target to affect this critical cell regulatory pathway.
INTRODUCTION
We recently described an animal model in which primary
genetic lesions in bone marrow (BM) stromal cells resulted
in abnormal hematopoiesis in mice and the rare develop-
ment of acute leukemia (Raaijmakers et al., 2010). While
evaluating three leukemias that emerged in the setting of
this aberrant stroma, we noted that two of them had a
shared chromosomal abnormality. Reasoning that this rep-
resented a highly nonstochastic event, we assessed the
open reading frames in the altered region and found that
two of them putatively encoded transmembrane mole-
cules. Since transmembrane molecules might represent a
means by which an altered BM stroma could select for
abnormal hematopoietic stem/progenitors, we focused on
these molecules. One of these, C14ORF37, is the subject
of this report. Using overexpression and knockdown con-
structs, we found that C14ORF37 encodes a protein with
unique characteristics in modulating a speciﬁc aspect of
the AKT/mTOR growth and differentiation pathway in
hematopoietic cells.
Activation of AKT in hematopoiesis as induced experi-
mentally by deletion of Pten leads to a myeloproliferative
syndrome and eventual loss of hematopoietic stem cells
(Kharas et al., 2010; Yilmaz et al., 2006; Zhang et al.,
2006). This is mTOR dependent, as loss of hematopoietic
stem cells can be rescued by rapamycin. The mTOR com-
plex implicated in this process appears to be mTORC1,
since experimental deletion of Raptor (a canonical compo-
nent of mTORC1) similarly resulted in hematopoietic fail-
ure as evidenced by a lack of reconstituting ability upon
transplantation (Kalaitzidis et al., 2012; Magee et al.,
2012). In addition, pharmacological inhibition of mTOR
resulted in antileukemia effects in a mouse model of acute
myeloid leukemia (AML) (Zeng et al., 2007, 2012). In some
leukemia-initiating cells, however, the AKT pathway
appears to play a different role. AKT activation at position
S473 is associated with subsequent phosphorylation of
FOXOs, which reduces the ability of the FOXOs to enter
the nucleus and serve as transcriptional regulators. How-
ever, 40% of human AML shows a gene-expression signa-
ture consistent with Foxo transcriptional activity, and
FOXO inhibition in human and mouse AML cells results
in terminal differentiation (Sykes et al., 2011). Deletion of
Foxo1, Foxo3, and Foxo4 in a mouse model of AML resulted
in differentiation and loss of leukemia-initiating cells.
Therefore, the AKT pathway may have complex roles in
the proliferation and differentiation abnormalities associ-
ated with myeloid malignancies.
Acute lymphocytic leukemia (ALL) is more clearly driven
by activation of the AKT/mTOR pathway. Rapamycin was
shown to reduce the leukemia burden in xenograft models
of B cell ALL (B-ALL), and reducing AKT activity by
anti-connective tissue growth factor (anti-CTGF) therapy
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(T-ALL), clonal dominance was shown in cells where AKT
activation increased and was associated with resistance to
antitumor glucocorticoid therapy (Blackburn et al., 2014).
Another study showed that inhibition of AKT could over-
come glucocorticoid resistance (Piovan et al., 2013). The
T-ALL that emerged with either Pten deﬁciency or with
NOTCH activation was dependent upon very speciﬁc ele-
ments of the AKT pathway, in particular, the mTORC2
complex. This complex includes RICTOR, among other
proteins, and is upstream of AKT, phosphorylating AKT at
S473. Deletion of Rictor is capable of inhibiting T-ALL asso-
ciated with either Pten deletion (Kalaitzidis et al., 2012)o r
NOTCH activation (Lee et al., 2012). Therefore, mTORC2
is critical for some lymphoid leukemias. Here, we report
that C14ORF37 encodes a protein that is capable of
interacting with and inhibiting the function of mTORC2.
This distinctive transmembrane molecule may be a modu-
lator of growth-regulator signals conveyed from the BM
microenvironment.
RESULTS
Impact of UT2 on the mTORC2/AKT/FOXO Axis
C14ORF37 encodes a putative type I transmembrane pro-
tein with an intracytoplasmic tail that has no clear
functional homologies. C14ORF37 is expressed by BM
hematopoietic cells, with the most abundant message
being found in the hematopoietic stem and progenitor
cell (HSPC)-enriched Lin
 SCA1
+c-KIT
+ (LSK) fraction and
dominantly present in BM (Figures S1A–S1C available on-
line). To determine its function, we transduced multiple
small hairpin RNA (shRNA) constructs targeting C14orf37
and overexpressed cDNA in primary mouse hematopoietic
cells and, for some assays, FLAG-tagged cDNA expressed in
HEK293T cells. Three shRNAs targeting distinctive regions
within the C14orf37 transcript provided effective knock-
down (Figures S1D and S1E) and comparable effects (data
are presented using one shRNA displaying >90% inhibi-
tion). Because the molecule was studied as a potential
mediator of altered hematopoietic cell growth, we exam-
ined growth-regulatory pathways to determine whether
any were altered in the context of changing the levels of
C14ORF37 (called UT2 for reasons given below). Although
there was no effect on ERK phosphorylation or PP2A,
PTEN, PDK1, or PI3K p85 levels (Figure 1A), there was evi-
dence that UT2 shRNA increased the level of pAKT
S473 (Fig-
ures 1A–1C and S1F–S1H).
Phosphorylation of AKT at S473 occurs through the
RICTOR-containing complex with mTOR, mTORC2.
Notably, the PDK1 phosphorylation site on AKT, T308,
was not consistently changed. To further assess the impact
of UT2 on AKT, we evaluated the downstream targets
of pAKT
T308, including pmTOR
S2448 and pPRAS40
T246,
which were not altered (Figures 1A, 1D, and S1F). Also,
pAKT
T308 results in activation of the RAPTOR-containing
mTOR complex, mTORC1, so we evaluated the targets of
mTORC1 activation: pS6
S235/236 and p4EBP1
T37/46. Neither
of these was altered. Together, these data indicate that UT2
knockdown does not inﬂuence mTORC1. These results
were further validated by overexpression of UT2: decreased
pAKT
S473 and RICTOR levels were noted, but no consistent
changes were observed in mTORC1 components or targets.
These data suggest that UT2 (C14ORF37) modulates
RICTOR and alters mTORC2-dependent AKT phosphoryla-
tion without affecting mTORC1. Therefore, we have
named C14ORF37 upstream of mTORC2 (UT2) in refer-
ence to itsdistinctive relationship with the mTOR complex
containing RICTOR.
With a change in mTORC2 activity, one would expect
known substrates such as PKCa (Guertin et al., 2006) and
SGK (assayed by NDRG1 [Garcı ´a-Martı ´nez and Alessi,
2008] phosphorylation), as well as the effects of pAKT
S473,
to be perturbed. We found that UT2 shRNA increased
pPKCa
S657 and pNDRG1
T346, whereas overexpression of
UT2 reduced it (Figures 1A, 1C, and S1F). Similarly,
pAKT
S473 is known to phosphorylate FOXOs, resulting in
their retention in the cytoplasm and reduced transcrip-
tional activity. Inhibiting UT2 by shRNA led to increased
pAKT
S473 and a consequent increase in the levels of
pFOXO3s (S253, T32, and S318/321). The converse was
seen when UT2 was overexpressed in these cells (Figures
1A, 1C, and S1F). Together, these results argue that levels
ofUT2modulate theactivityofmTORC2 andtwo ofitspri-
mary known targets with expected biochemical results
downstream. UT2 decreases mTORC2 functional activity.
UT2 Negatively Regulates AKT Signaling via
Interaction with mTORC2
Given the impact of UT2 on the mTORC2/AKT/FOXOs
axis, we postulated that UT2 may physically interact with
RICTOR. To address this, we ﬁrst assessed the cellular
distribution of endogenous UT2 and RICTOR by immuno-
staining (Figure S2A). Primary hematopoietic cells from
wild-type (WT) and Rictor-deﬁcient animals were stained
withantibodiesagainstUT2andRICTOR,andthisrevealed
that a substantial proportion of UT2 colocalized with
RICTOR. To examine whether the effects of UT2 reﬂected
a physical interaction with candidate target proteins,
we conducted immunoprecipitation (IP) experiments on
HEK293T cells expressing a FLAG-UT2 fusion or FLAG-
UT2 fusion with the cytoplasmic region of UT2 deleted
(FLAG-UT2-DC) (Figure 2A). Anti-FLAG monoclonal IP
demonstrated coprecipitation with UT2 and RICTOR
by western blot. Furthermore, the RICTOR interaction
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by the FLAG-UT2-DC construct. We therefore pursued the
interaction further in primary hematopoietic cells from
animals with conditional homozygous deletion of Rictor
(Figure 2B) and again demonstrated coIP of UT2 and
RICTOR in control cells that was lost in Rictor-deleted cells
(the faint band represents incomplete deletion). To assess
other possible molecular interactions of UT2, we used a
panel of antibodies for other known components of
mTOR complexes and performed IP and western blot (Fig-
ure S2B). UT2 IP brought down RICTOR, but did not bring
down RAPTOR, a canonical mTORC1 member. Cumula-
tively, these data indicate that UT2 interacts with
mTORC2, but not mTORC1.
To further verify a direct interaction between UT2 and
RICTOR, we generated in vitro-translated proteins and
conducted IP experiments. IP of UT2 and RICTOR demon-
strated coIP indicative of a direct interaction between the
proteins in vitro (Figure 2C, left). When the same experi-
ment was conducted with UT2 in which the C-terminal
cytoplasmic domain had been deleted, the results failed
todemonstrateanycoIPofUT2DCandRICTOR(Figure2C,
right). Therefore, UT2 directly interacts with RICTOR and
does so in a manner that depends on its cytoplasmic
domain.Next,weexaminedwhetherUT2alteredthephos-
phorylation levels of pAKT
S473 in primary hematopoietic
cells from animals conditionally deﬁcient in Rictor (Fig-
ure 2D). The effects of shUT2 on pAKT
S473 were not
Figure 1. UT2 Regulates the mTORC2/AKT/FOXO Axis in Primary Hematopoietic Cells
(A) Primary hematopoietic cells from cells overexpressing or depleted for UT2 were analyzed by western blotting using the indicated
antibodies. ACTIN was used as a loading control (n = 2–3 experiments).
(B) Graphs show the fold change of the indicated normalized protein ratios (pAKT
S473/AKT and RICTOR/ACTIN) in (A). Data are means ±
SEM (n = 3 experiments).
(C and D) Flow cytometry was performed on hematopoietic cells overexpressing or shRNA-depleted for UT2. Quantiﬁcation of the fold
change in mean ﬂuorescence intensity for the indicated phosphoprotein in these cells is shown. Data are means ± SEM (n = 2–3
experiments; two-tailed, unpaired t test). *p < 0.05, **p < 0.01.
See also Figure S1.
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lates pAKT
S473 in primary hematopoietic cells through
RICTOR. We then performed mTORC2 in vitro kinase
assays to deﬁne whether UT2 had a meaningful impact
on mTORC2 function. mTORC2 was isolated from lysates
ofHEK293TcellsbycoIPwithRICTORandproportionately
included other components of the complex, including
mTOR and mLST8 (Figure 2E). The HEK293Tcells were ex-
pressing FLAG-UT2 or controls. AKT was exogenously
added as a substrate (note: it was not immunoprecipitated
with RICTOR). Phosphorylation of AKTat S473 was dimin-
ished in the presence of FLAG-UT2 (Figure 2E), indicating
that UT2 inhibits mTORC2 phosphorylation of AKT.
Furthermore, shRNA against UT2 in primary hemato-
poietic cells demonstrated increased pAKT
S473 levels that
were accentuated by insulin or serum stimulation of
starved cells (Figure S2C). Together, these data indicate
that UT2 inhibits mTORC2 kinase activity as evidenced
by phosphorylation of AKT.
FOXO3 Directly Regulates Ut2 Expression In Vivo
Given the impact of UT2 on the mTORC2/AKT/FOXO axis
and the importance of FOXOs in regulating hematopoietic
function (Paik et al., 2007; Tothova et al., 2007), we as-
sessed whether FOXOs inﬂuenced UT2 expression. Mouse
primary hematopoietic cells were transduced with recom-
binant retroviruses expressing FOXO3 WT, FOXO3 triple
mutant (AAA, FOXO3 AKT-resistant and active form)
(Brunet et al., 1999), or myristoylated AKT (myr-AKT,
which leads to diminished FOXO activity) (Kharas et al.,
2010; Kohn et al., 1996)( Figure 3A). Enforced expression
of either the WT or AKT-resistant mutant version of
FOXO3 activated Ut2 expression (Figure 3B). Primary
hematopoietic cells derived from mice lacking functional
puriﬁed Foxo1, Foxo3, and Foxo4 alleles (hereafter termed
Foxo1/3/4 KO) displayed signiﬁcantly lower levels of Ut2
transcripts compared with the WT (Figure 3C), suggesting
that members of the FOXO family regulate Ut2 expression
in vivo.
Figure 2. UT2 Interacts with mTORC2/
RICTOR and Regulates Their Activities in
Primary Hematopoietic Cells
(A) HEK293T cells transfected with vectors
encoding either Flag-UT2 full length or
Flag-UT2 DC mutant were lysed and sub-
jected to IP using an antibody directed
against FLAG and IgG, respectively. The
resulting precipitates and corresponding
whole-cell lysates (WCLs) were subjected to
western blot analysis using the indicated
antibodies (n = 3 experiments).
(B) RICTOR or UT2 was immunoprecipitated
from WT and conditional homozygous
deletion of Rictor BM cells and subjected to
western blot analysis using the indicated
antibodies (n = 6 mice pool per each ge-
notype).
(C) In vitro-translated FLAG-UT2 full length
(left) or FLAG-UT2 DC mutant (right) pro-
teins were subjected to IP using the
indicated antibodies in the presence of
in vitro-translated myc-RICTOR protein
(n = 2–3 experiments).
(D) WT and conditional homozygous dele-
tion of Rictor BM cells expressing shRNA
constructs against control or UT2 were
subjected to western blot analysis using the
indicated antibodies (n = 3 mice pool per
each genotype).
(E) Endogenous RICTOR was immunopre-
cipitated from control and HEK293T cells
transfected with vectors encoding FLAG-UT2 full length and subjected to in vitro kinase assays using recombinant inactive AKT as
the substrate and pAKT
S473 as the readout. An immunoblot for the levels of RICTOR, mTOR, and mLST8 in each immunoprecipitate is shown
(n = 3 experiments).
See also Figure S2.
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there is a putative FOXO3-binding site embedded approx-
imately 7 kb upstream of the transcriptional start site
(Figure S3A). Chromatin IP (ChIP) with FOXO3-speciﬁc
antibodies in primary hematopoietic cells and ﬁbroblast
cells showed that FOXO3 binds to this conserved site
within the Ut2 promoter in vivo (Figures 3D and S3B).
Furthermore, FOXO3 can activate luciferase expression
driven by a minimal promoter containing the putative
FOXO3 consensus sequence found in the Ut2 promoter
(Figure 3E). Collectively, these data show that FOXO3
directly regulates the transcription of Ut2. Moreover,
UT2 regulation of Rictor levels was evaluated and found
to occur at the level of transcription (Figure S3C). The
evidence therefore suggests that FOXO3 is a regulator of
UT2 that can feed forward to further increase FOXO3
activity by inhibiting AKT
S473 phosphorylation (Fig-
ure 4D). However, this is recognized to be only a
partial characterization of the mechanisms that regulate
FOXO3 and expression of UT2.
Impact of UT2 on NOTCH-Associated T-ALL
To determine whether UT2 altered the function of hemato-
poietic cells, we chose to use a model of malignancy
because it was previously shown to be a striking phenotype
of mTORC2 deﬁciency. More than 50% of human T-ALL
cells depend on NOTCH mutations for their growth or
viability (Weng et al., 2004), and a previous study showed
that mTORC2 facilitates NOTCH-driven T-ALL develop-
ment, whereas Rictor depletion substantially prolongs
survival (Lee et al., 2012). Furthermore, in settings of Pten
deletion,T-ALLdevelopsrapidlyexceptwhenthemTORC2
component,Rictor,isdeleted(Kalaitzidisetal.,2012;Magee
et al., 2012). To examine whether UT2 affects T-ALL, he-
matopoietic BM precursors were transduced with a consti-
tutively active form of NOTCH1 (intracellular NOTCH1
[ICN]) and transplanted into recipient mice (Chiang
et al., 2008; Lee et al., 2012; Piovan et al., 2013)( Figure 4A).
Mice transplanted with UT2 overexpressing ICN
+ cells dis-
played signiﬁcantly prolonged disease survival, whereas
the animals with knocked-down UT2 died signiﬁcantly
Figure 3. FOXO3 Activates Ut2 Expres-
sion in Primary Hematopoietic Cells
(A) Schematic representation of a gene-
expression assay in primary hematopoietic
cells.
(B) Quantitative RT-PCR for Ut2 expression.
Data are means ± SEM (n = 3 experiments;
two-tailed, unpaired t test). **p < 0.01.
(C) Ut2 expression in primary hematopoi-
etic cells from WT and Foxo1/3/4 KO mice.
Data are means ± SEM (n = 3 mice per each
genotype; two-tailed, unpaired t test).
**p < 0.01.
(D) ChIP analysis for MIG-FOXO3 or mock
expressing BM cells, using the indicated
antibodies. Data are means ± SEM (n = 3
experiments; two-tailed, unpaired t test).
**p < 0.01.
(E) Relative luciferase activity of FOXO3 on
the Ut2 promoter. Data are means ± SEM
(n = 4 experiments; two-tailed, unpaired
t test). **p < 0.01.
See also Figure S3.
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Transmembrane Inhibitor of mTORC2Figure 4. UT2 Extends the Disease Latency of T-ALL in Mice
(A) Expression proﬁle of the indicated genes before BM transplantation (BMT) assays. Primary hematopoietic cells from C57BL/6
5-ﬂuorouracil (5-FU)-injected donors with cells overexpressing or shRNA-depleted for UT2 were transduced with overexpressing
intracellular NOTCH1 (ICN), and then BMT assays were performed. Data are means ± SEM (n = 3 experiments; two-tailed, unpaired t test).
*p < 0.05. **p < 0.01. ‘‘Control’’ represents ICN-transduced cells.
(B) Kaplan-Meier survival curves for recipient mice after transplantation of ICN1-transduced BM cells from cells overexpressing or shRNA-
depleted for UT2 as described in (A) (n = 10–11 biological replicated experiments, log rank test). **p < 0.01.
(C) Flow-cytometry analysis of various hematopoietic tissues from T-ALL recipient mice in (A) (n = 8–9 biological replicated experiments).
(D) Expression of phosphorylated AKT on S473 in spleen and thymus from recipient mice in (A). Animals were examined when they were
moribund. Data are means ± SEM (n = 8–9 biological replicated experiments, two-tailed, unpaired t test). **p < 0.01.
(E) UT2 negatively regulates AKT signaling by modulating the activity of RICTOR/mTORC2.
See also Figure S4.
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Transmembrane Inhibitor of mTORC2morerapidly(Figure4B).Anexaminationofhematopoietic
tissues by ﬂow cytometry revealed aberrant T cells in the
thymus, spleen, and BM consistent with leukemic disease,
although survival was prolonged in UT2-overexpressing
cells (Figure 4C). The changes in mortality correlated
with different levels of pAKT
S473 as anticipated from UT2
modulation (Figure 4D). Together, these results demon-
strate that UT2 is capable of affecting the outcome of
NOTCH-associated T-ALL in association with changes in
mTORC2 activity.
DISCUSSION
These data identify a transmembrane molecule that nega-
tively regulates AKT signaling via modulation of mTORC2
(Figure4E).ItjoinsthesmallnumberofmTORC2upstream
interactors, such as ribosome components (Zinzalla et al.,
2011).Itstransmembrane,putativecell-surfacelocalization
suggests that it may be a means by which exogenous cues
can dampen mTORC2 activation. We identiﬁed this mole-
cule by virtue of its ampliﬁcation in the context of a micro-
environmentally induced AML (Raaijmakers et al., 2010),
in line with AKT playing a tumor-suppressive role in a sub-
stantial proportion of patients with this disease and in
maintenance of leukemia stem cells in an animal model
(Sykes et al., 2011). However, we cannot draw a direct link
between UT2 ampliﬁcation and aberrant signals from the
modiﬁed stroma in that model. Of note, UT2 had modest
effects on normal hematopoietic function (Figure S4). We
did observe that enforced UT2-expressing donor cells
contributed to lower levels of blood cells (Figure S4B), the
frequency of Lin
 SCA1
+c-KIT
+ (L
 S
+K
+) cells (Figure S4C),
and colony formation as compared with control cells (Fig-
ureS4D).Moreover,hematopoieticcellsfromtheBMofan-
imalswith thealtered microenvironmentshowedevidence
of decreased pAKT
S473 (FigureS1I) consistent with a role for
UT2, but whether that was then selected for in the emer-
gence of the leukemia cannot be discerned by our studies
todate.InT-ALL,wheremTORC2/AKTplaysacleareronco-
genic role, wewere ableto demonstratethat UT2 could bea
therapeutic target to modulate that disease. Collectively,
our work points to the value of models that can be used
to examine niche contributions to oncogenesis and reveals
a previously unrecognized transmembrane modulator of a
critical pathway with therapeutic implications for cancer.
EXPERIMENTAL PROCEDURES
Mice and Animal Procedures
All mice were kept in a speciﬁc pathogen-free facility at Massachu-
setts General Hospital. All mice studies and breeding were carried
out under the approval of Institutional Animal Care and Use Com-
mittee of Massachusetts General Hospital. Foxo1/3/4
ﬂoxed;Mx1-Cre
(Paik et al., 2007; Sykes et al., 2011; Tothova et al., 2007) and
Rictor
ﬂoxed;Mx1-Cre (Shiota et al., 2006) mice were generated previ-
ously. ToexamineT-ALLmodelin mice, hematopoietic BMprecur-
sors were transduced with a constitutively active form of NOTCH
(ICN) and transplanted into recipient mice (Chiang et al., 2008;
Lee et al., 2012; Piovan et al., 2013). See the Supplemental Experi-
mental Procedures for further details.
Protein Analyses
Western blot analysis was carried out according to standard
methods as previously described (Sykes et al., 2011). For standard
IP experiments, all cells,with theexceptionof thoseusedto isolate
mTORC, were lysed with Triton X-100-containing lysis buffer as
previouslydescribed(Petersonetal.,2009).ForIPsofmTORC,cells
were lysed in mTORC lysis buffer (ice-cold CHAPS-containing lysis
buffer) as previously described (Guertin et al., 2006; Huang et al.,
2008; Kim et al., 2002; Peterson et al., 2009; Sarbassov et al.,
2004, 2005). The mTORC2 in vitro kinase assay was performed
as described previously (Guertin et al., 2006; Huang et al., 2008;
Jacintoetal.,2006;Kimetal.,2002;Petersonetal.,2009;Sarbassov
et al., 2004, 2005). ChIP experiments were performed with the use
of a ChIPAssay Kit (Millipore) according to the manufacturer’s in-
structions (Lee et al., 2008). For serum and insulin stimulation ex-
periments, BM cells expressing UT2 or shRNA-mediated depletion
of UT2 BM cells were deprived of serum for 3 hr and then fetal
bovine serum or insulin was add back at 10% serum or 1 mg/mL in-
sulin concentration, respectively, for 30 min prior to lysis (Guertin
et al., 2006; Jacinto et al., 2006). See the Supplemental Experi-
mental Procedures for further details.
Real-Time Quantitative RT-PCR
Real-time quantitative RT-PCR was performed as previously
described (Lee et al., 2008, 2011).
Flow Cytometry and Antibodies
BM cells and leukocytes were harvested and subjected to red cell
lysis (Leeet al., 2011; Sykes et al., 2011). Phosphoﬂow experiments
were performed as previously described (Kalaitzidis et al., 2012;
Sykes et al., 2011). See the Supplemental Experimental Procedures
for further details.
Statistical Analysis
The sample size required for experiments was estimated based on
preliminary data. In vitro and in vivo data were analyzed with a
two-tailed, unpaired Student’s t test (GraphPad Prism; GraphPad
Software) and SigmaPlot 10.0 software (SPSS). Values of p < 0.05
were considered statistically signiﬁcant (*p < 0.05; **p < 0.01).
The Kaplan-Meier log rank test was used to analyze mouse survival
data using GraphPad Prism. No blinding or randomization was
performed for any of the experiments.
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